7 days ago
CYTK
AnalystsSrikripa DevarakondaSrikripa Devarakonda's Stock Forecasts
AnalystsSrikripa Devarakonda
Analyst Ranking
Top 15%
#747 out of 5188 analysts
Average Return
+13.52%
Win Rate
51%40 out of 79
Risk vs Reward
Poor
Good
Srikripa Devarakonda's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Terns Pharmaceuticals IncTERN | +346.82% | $8.50 | $37.98 | 2025-10-14 - 2026-02-09 | Strong Buy |
Verastem IncVSTM | +229.72% | $2.49 | $8.21 | 2024-08-12 - 2025-08-12 | Strong Buy |
Mbx Biosciences IncMBX | +165.45% | $13.95 | $37.03 | 2025-10-14 - 2026-02-09 | Strong Buy |
Edgewise Therapeutics IncEWTX | +131.48% | $7.56 | $17.50 | 2023-06-27 - 2024-06-27 | Strong Buy |
Terns Pharmaceuticals IncTERN | +117.90% | $17.43 | $37.98 | 2025-11-03 - 2026-02-09 | Strong Buy |
Srikripa Devarakonda Analyst Color
Get additional color on Srikripa Devarakonda's coverage of popular stocks
a month ago
PTGX
2 months ago
KYMR
2 months ago
KYMR
3 months ago
MDGL
a year ago
LLY
a year ago
PFE
a year ago
EWTX
a year ago
SRRK
a year ago
LLY
2 years ago
LLY
2 years ago
LLY
2 years ago
KYMR
Srikripa Devarakonda's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Biogen IncBIIB | 6 | Hold | $193.00 | -0.42% | Maintains | a day ago |
Cytokinetics IncCYTK | 5 | Strong Buy | $92.00 | +45.20% | Maintains | 7 days ago |
Protagonist Therapeutics IncPTGX | 4 | Strong Buy | $110.00 | +32.02% | Maintains | a month ago |
Septerna IncSEPN | 1 | Strong Buy | $34.00 | +27.87% | Initiates Coverage On | 2 months ago |
Kymera Therapeutics IncKYMR | 6 | Strong Buy | $116.00 | +46.80% | Maintains | 2 months ago |
Terns Pharmaceuticals IncTERN | 4 | Strong Buy | $56.00 | +47.45% | Maintains | 2 months ago |
Madrigal Pharmaceuticals IncMDGL | 2 | Strong Buy | $640.00 | +31.08% | Maintains | 3 months ago |
Incyte CorpINCY | 12 | Hold | $93.00 | -14.70% | Reiterates | 3 months ago |
Scholar Rock Holding CorpSRRK | 5 | Strong Buy | $44.00 | -8.05% | Maintains | 4 months ago |
Viatris IncVTRS | 1 | Strong Buy | $15.00 | -3.60% | Initiates Coverage On | 4 months ago |
Mbx Biosciences IncMBX | 1 | Strong Buy | $50.00 | +35.03% | Initiates Coverage On | 4 months ago |
Regeneron Pharmaceuticals IncREGN | 8 | Strong Buy | $812.00 | +4.07% | Maintains | 6 months ago |
Arvinas IncARVN | 1 | Hold | $11.00 | -17.23% | Downgrades | 9 months ago |
Keros Therapeutics IncKROS | 5 | Strong Buy | $25.00 | +42.61% | Maintains | 10 months ago |
Eli Lilly & CoLLY | 4 | Strong Buy | $1,038.00 | N/A | Maintains | a year ago |
Abbvie IncABBV | 3 | Strong Buy | $217.00 | N/A | Maintains | a year ago |
Pfizer IncPFE | 1 | Strong Buy | $32.00 | N/A | Maintains | a year ago |
Edgewise Therapeutics IncEWTX | 6 | Strong Buy | $50.00 | N/A | Maintains | a year ago |
Biomea Fusion IncBMEA | 1 | Strong Buy | $54.00 | N/A | Upgrades | a year ago |
Verastem IncVSTM | 7 | Strong Buy | $15.00 | N/A | Maintains | a year ago |
Nurix Therapeutics IncNRIX | 1 | Strong Buy | $36.00 | N/A | Initiates Coverage On | 2 years ago |
Affimed NvAFMDQ | 2 | Strong Buy | $60.00 | N/A | Maintains | 2 years ago |
9 Meters Biopharma IncNMTRQ | 3 | Hold | $38.00 | N/A | Downgrades | 3 years ago |
Constellation Pharmaceuticals IncCNST | 2 | Hold | $34.00 | N/A | Downgrades | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.